Fragonomics: Fragment-based drug discovery

Current Opinion in Chemical Biology

Volumn 9, Issue 4, 2005, Pages 366-370

  Zartler, Edward R ^a   Shapiro, Michael J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOM; BINDING AFFINITY; BIOASSAY; CALCULATION; CHEMISTRY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MARKETING; DRUG SCREENING; FRAGONOMICS; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; MOLECULAR SIZE; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PHYLOGENY; PROBABILITY; REVIEW; SCREENING; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS;

EID: 22544488422     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.05.002     Document Type: Review

References (41)

1. H. Kubinyi Drug research: myths, hype, and reality Nat Rev Drug Discov 2 2003 665 668 This is an excellent article that discusses some of the misperceptions that exist around drug discovery, particularly the current 'screen for drug' paradigm.
2. D.C. Rees, M. Congreve, C.W. Murray, and R. Carr Fragment-based lead discovery Nat Rev Drug Discov 3 2004 660 672
3. D.A. Erlanson, R.S. McDowell, and T. O'Brien Fragment-based drug discovery J Med Chem 47 2004 3463 3482
4. A. Gill New lead generation strategies for protein-kinase inhibitors-fragment based screening approaches Mini Rev Med Chem 4 2004 301 311
5. D. Fattori Molecular recognition: the fragment approach in lead generation Drug Discov Today 9 2004 229 238
6. M.M. Hann, A.R. Leach, and G. Harper Molecular complexity and its impact on the probability of finding leads for drug discovery J Chem Inf Comput Sci 41 2001 856 864
7. M. Vieth, M.G. Siegel, R.E. Higgs, I.A. Watson, D.H. Robertson, K.A. Savin, G.L. Durst, and P.A. Hipskind Characteristic physical properties and structural fragments of marketed oral drugs J Med Chem 47 2004 224 232 This paper discusses the physical properties of oral drugs. Orally available molecules tend to be lighter and have fewer H-bond donors, acceptors, and rotatable bonds than non-orally bioavailable drugs.
8. C.A. Lipinski, F. Lombardo, B. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26
9. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J Pharmacol Toxicol Methods 44 2000 235 249
10. J. Mestres, and G.H. Veeneman Identification of "latent hits" in compound screening collections J Med Chem 46 2003 3441 3444
11. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug Discov Today 9 2004 430 431 This paper presents a simple way to evaluate compounds as they move along the discovery pathway so that the optimal binding molecules can be easily discerned.
12. P.R. Andrews, D.J. Craik, and J.L. Martin Functional group contributions to drug-receptor interactions J Med Chem 27 1984 1648 1657
13. G.L. Card, L. Blasdel, B.P. England, C. Zhang, Y. Suzuki, S. Gillette, D. Fong, P.N. Ibrahim, D.R. Artis, and G. Bollag A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat Biotechnol 23 2005 201 207
14. P.J. Hajduk, S.F. Betz, J. Mack, X. Ruan, D.L. Towne, C.G. Lerner, B.A. Beutel, and S.W. Fesik A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening J Biomol Screen 7 2002 429 432
15. A.M. Aronov, and G.W. Bemis A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors Proteins 57 2004 36 50
16. N. Baurin, F. Aboul-Ela, X. Barril, B. Davis, M. Drysdale, B. Dymock, H. Finch, C. Fromont, C. Richardson, and H. Simmonite Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets J Chem Inform Comput Sci 44 2004 2157 2166 This paper describes the complete rationale and construction of a fragment library to be used for NMR-based fragment screening. This rationale applies to all fragment libraries.
17. E.R. Zartler, J. Yan, H. Mo, A.D. Kline, and M.J. Shapiro 1D NMR methods in ligand-receptor interactions Curr Top Med Chem 3 2003 25 37
18. Zartler ER, Shapiro MJ: Protein NMR-based screening for drug discovery. Curr Pharm Des 2005, in press.
19. H.O. Villar, J. Yan, and M.R. Hansen Using NMR for ligand discovery and optimization Curr Opin Chem Biol 8 2004 387 391
20. E.R. Zartler, J. Hanson, B.E. Jones, A.D. Kline, G. Martin, H. Mo, M.J. Shapiro, R. Wang, H. Wu, and J. Yan RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery J Am Chem Soc 125 2003 10941 10946 This paper describes for the first time in any format the screening of multiple proteins simultaneously.
21. J. Weigelt, M. van Dongen, J. Uppenberg, J. Schultz, and M. Wikstrom Site-selective screening by NMR spectroscopy with labeled amino acid pairs J Am Chem Soc 124 2002 2446 2447
22. Y-S. Wang, D. Liu, and D.F. Wyss Competition STD NMR for the detection of high-affinity ligands and NMR-based screening Magn Reson Chem 42 2004 485 489
23. M. Mayer, and B. Meyer Characterization of ligand binding by saturation transfer difference NMR spectroscopy Angew Chem Int Ed Engl 38 1999 1784 1788
24. P.J. Hajduk, J.C. Mack, E.T. Olejniczak, C. Park, P.J. Dandliker, and B.A. Beutel SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes J Am Chem Soc 126 2004 2390 2398
25. J.R. Huth, R. Mendoza, E.T. Olejniczak, R.W. Johnson, D.A. Cothron, Y. Liu, C.G. Lerner, J. Chen, and P.J. Hajduk ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens J Am Chem Soc 127 2005 217 224
26. S. Vanwetswinkel, R.J. Heetebrij, J. van Duynhoven, J.G. Hollander, D.V. Filippov, P.J. Hajduk, and G. Siegal TINS, Target Immobilized NMR Screening: an efficient and sensitive method for ligand discovery Chem Biol 12 2005 207 216
27. D.F. Wyss, A. Arasappan, Senior Mm, Y.-S. Wang, B.M. Beyer, F.G. Njoroge, and M.A. McCoy Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening J Med Chem 47 2004 2486 2498
28. R. Fattorusso, D. Jung, K.J. Crowell, M. Forino, and M. Pellecchia Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach J Med Chem 48 2005 1649 1656
29. 19F relaxation measurements for the study of fluorinated ligand-receptor interactions J Magn Reson 153 2001 32 47
30. P.J. Hajduk, S.B. Shuker, D.G. Nettesheim, R. Craig, D.J. Augeri, D. Betebenner, D.H. Albert, Y. Guo, R.P. Meadows, and L. Xu NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability J Med Chem 45 2002 5628 5639 An example of the Fragonomics approach used in lead optimization.
31. L. Fielding, D. Fletcher, S. Rutherford, J. Kaur, and J. Mestres Exploring the active site of human Xa protein by NMR screening of small molecule probes Org Biomol Chem 1 2003 4235 4241
32. M.J. Hartshorn, C.W. Murray, A. Cleasby, M. Frederickson, I.J. Tickle, and H. Jhoti Fragment-based lead discovery using X-ray crystallography J Med Chem 48 2005 403 413
33. A. Gill, M. Frederickson, A. Cleasby, S.J. Woodhead, M.G. Carr, A.J. Woodhead, M.T. Walker, M. Congreve, L.A. Devine, and D. Tisi Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation J Med Chem 48 2005 414 426
34. W.J. Sanders, V. Nienaber, C.G. Lerner, J.O. McCall, S.M. Merrick, S.J. Swanson, J.E. Harlan, V.S. Stoll, G.F. Stamper, and S.F. Betz Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization J Med Chem 47 2004 1709 1718
35. T.L. Blundell, and S. Patel High-throughput X-ray crystallography for drug discovery Curr Opin Pharmacol 4 2004 490 496
36. G. Liu, Z. Xin, Z. Pei, P.J. Hajduk, C. Abad-Zapatero, C.W. Hutchins, H. Zhao, T.H. Lubben, S.J. Ballaron, and D.L. Haasch Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor J Med Chem 46 2003 4232 4235
37. 2 receptor ligands using the fragment approach Bioorg Med Chem 15 2005 585 588
38. S.R. Inglis, C. Stojkoski, K.M. Branson, J.F. Cawthray, D. Fritz, E. Wiadrowski, S.M. Pyke, and G.W. Booker Identification and specificity studies of small-molecule ligands for SH3 protein domains J Med Chem 47 2004 5405 5417
39. M. Rosini, V. Andrisano, M. Bartolini, M.L. Bolognesi, P. Hrelia, A. Minarini, A. Tarozzi, and C. Melchiorre Rational approach to discover multipotent anti-Alzheimer drugs J Med Chem 48 2005 360 363
40. D.A. Erlanson, J.W. Lan, C. Wiesman, T.N. Luong, R.L. Simmons, W.L. DeLano, I.C. Choong, M.T. Burdett, W.M. Flanagan, and D. Lee In situ assembly of enzyme inhibitors using extended tethering Nat Biotechnol 21 2003 308 314
41. J. Hyde, A.C. Braisted, M. Randal, and M.R. Arkin Discovery and characterization of cooperative ligand binding in the adaptive region of Interleukin-2 Biochemistry 42 2003 6475 6483